Xinjiang national medicine made great efforts to catch up with the times

On June 6, the 6th executive meeting of the 12th people's Government of Xinjiang Uygur Autonomous Region was held to study and approve the opinions of the people's Government of Xinjiang Uygur Autonomous Region on supporting and promoting the development of traditional Chinese medicine When Miao medicine, Tibetan medicine, Mongolian medicine and other local ethnic medicine enter the common people's homes with more and more momentum, how to make efforts to catch up with Xinjiang ethnic medicine with a long history, and even grow into a pillar industry to drive the local economy, has reached the critical stage of breaking the question Xinjiang national medicine ushered in the extraordinary development cold Wang Fan, a citizen of Urumqi, habitually bought zucamu granules to take In her mind, this kind of real estate ethnic medicine has good curative effect and quick effect Zukamu granules is one of the most recognized Uygur medicines in the market It has been listed in the latest 2012 edition of the national basic medicine catalogue and is also a National Protected Traditional Chinese medicine Xinjiang Uygur Pharmaceutical Co., Ltd is one of the three pharmaceutical enterprises that have the right to produce Zukamu granules in China, and also the largest national pharmaceutical manufacturer in our region at present Last year, the company's sales revenue reached 167 million yuan, accounting for half of the sales revenue of ethnic medicine in the region On the afternoon of June 4, the reporter came to the Uighur pharmaceutical industry in Urumqi Economic and Technological Development Zone, and the production workshop was busy In addition to Zukamu granules, Uighur pharmaceutical also has 8 dosage forms, including Tongzhi Surunjiang capsule, compound muniziqi granules, and 20 national pharmaceutical quasi brand products "Three shifts of production workers still cannot meet the market demand." Han Xiangzhi, deputy general manager, said that in the past five years, the company's sales revenue has been growing steadily at an annual rate of 30%, and is expected to reach 220 million yuan this year It is reported that in the market share of Uighur pharmaceutical industry, 50% of the market share is inside and outside the border, of which Zukamu granules account for about a quarter of the total market share According to the development ideas and Strategies of Uighur pharmaceutical industry, in the next five years, the company's sales scale will reach more than 500 million yuan, and it is necessary to make Uighur pharmaceutical products go abroad About 1.2km to the west of Uighur pharmaceutical industry is Xinjiang qikang habowei Pharmaceutical Co., Ltd Into the company, "modern Uygur medicine product development and high-tech industrialization" demonstration base, "modern Uygur medicine industrialization and characteristic medicine intensive processing" base and "Uygur Medicine Culture Museum" three brands are huge and eye-catching "After years of market development and promotion, our key product, Xipayi gingival fluid, has been ranked first in the market share of clinical oral botanical drugs for 8 consecutive years Now, 80% of our company's market is in the mainland With Zukamu and hanchuanzupa granules listed in the national basic drug catalog, there will be more than 1 billion yuan of output value space for these two kinds of drugs in the future, and Xinjiang national medicine has great potential! " Chairman Chen Jincheng is full of pride Zhao Xinjian, deputy director of the administration of traditional Chinese medicine and ethnic medicine of the autonomous region, said Xinjiang ethnic medicine mainly consists of Uygur Medicine, Kazakh medicine and Mongolian medicine Among them, in the long history of accumulation and application of research and development, Uygur medicine has formed a relatively complete and unique theoretical system, such as: four material theories, temperament theory, body fluid theory, etc., which explains the dialectical relationship between the human body and the outside world, and creates a set of therapeutic theories and drug theories for diagnosing and treating diseases It is the representative of ethnic medicine in our region, especially in the treatment of some difficult and miscellaneous diseases It has significant effect According to Wang Pingshan, director of the drug registry of the food and Drug Administration of the autonomous region, ethnic medicine represented by Uygur medicine has entered the fast lane of development According to the introduction, there are currently 11 ethnic medicine production enterprises in Xinjiang, 55 varieties of traditional Chinese medicine approved by the State Drug Administration; 45 ethnic medicine medical institutions, 22 preparation rooms of ethnic medicine medical institutions, 1545 preparation varieties; 87 traditional Chinese medicine prescriptions and 115 kinds of medicinal materials are included in the drug standard of the Ministry of Health (the volume of traditional Chinese Medicine) In July 2011, the autonomous region formulated the 12th Five Year Plan for the development of Xinjiang pharmaceutical industry, which explicitly encouraged and supported the innovation and technological transformation of national medicine technology, and actively promoted the industrialization of Uygur medicine Like traditional Chinese medicine, ethnic medicine has the advantages of "simplicity, convenience, efficiency and honesty", and also contains the characteristics of ethnic minorities It is understood that the clinical use of ethnic medicine accounts for more than 80% of the total amount of medicine in Xinjiang ethnic medical institutions, and the use of Uyghur medicine in individual Uyghur medical institutions is close to 100% The promulgation of the opinions of the people's Government of Xinjiang Uygur Autonomous Region on supporting and promoting the development of traditional Chinese medicine has opened a new stage of Xinjiang national medicine Previously, on May 18, Xinjiang biomedical innovation and entrepreneurship Park opened, marking the formal completion of the largest and most functional national biomedical research and production base in Xinjiang This series of actions is undoubtedly a positive signal for the innovation and development of the national medicine industry in our district In fact, from the national level to the autonomous region level, efforts have been made to support the formulation and improvement of national medicine quality standards, the improvement of national medicine quality standards, the team of national medicine review experts, the review system, the clinical base, the construction and certification of medicine planting base, etc from the aspects of policies, technologies and funds, so as to continuously improve the core competitiveness of national medicine The State Food and drug administration has listed the research project of the quality standard of traditional Chinese medicine in the action plan of national drug standard improvement In 2009 and 2010, a total of 9 million yuan was allocated to carry out the research on improving the standards of maintenance drugs In July 2011, the autonomous region formulated the 12th Five Year Plan for the development of Xinjiang pharmaceutical industry, explicitly encouraging and supporting the technological innovation and technological transformation of ethnic medicine, and actively promoting the industrialization process of Uygur medicine On September 14 of the same year, the people's Government of the autonomous region and the State Food and Drug Administration signed the framework agreement on accelerating the strategic cooperation in the development of Xinjiang's national drug industry with the focus on the maintenance of medicine, strengthening the cooperation from the National Bureau and the autonomous region, and promoting the development of Xinjiang's national drug industry at a high level Wang Pingshan introduced that since the signing of the framework agreement, relevant departments and units directly under the State Food and drug administration have organized experts to come to Xinjiang for many times to conduct in-depth research on the basic research and industrial development of ethnic medicine, and issued some practical policies and measures In addition, Xinjiang national medicine quality standard research project was included in the national action plan for improving drug standards, and 9 million yuan of special funds was allocated for the research of 90 Uygur medicine quality standards The drug evaluation center of the State Food and drug administration, as a member unit, participated in the scientific and technological project of guiding principles for clinical research of new medicines for 10 Uyghur medicine dominant diseases such as vitiligo At present, the scientific research project has completed the technical demonstration of Western medicine and Uyghur medicine experts This will play an important role in changing the current situation that there is no clinical evaluation standard for the research and development of new Uygur Medicine, initially establishing the review and approval system for new Uygur Medicine, improving the level of basic Uygur medicine research, and improving the scientific, normative and standardized construction of clinical research of new Uygur medicine In addition, the State Food and drug administration has held various trainings for many times to speed up the training of Xinjiang ethnic medicine professional and technical personnel, and improve the research and development, technical evaluation and testing capabilities of new medicines for Uygur medicine Since 2009, the autonomous region has allocated 30 million yuan of special funds every year to support the development of new traditional Chinese medicine In 2012, the administration of traditional Chinese medicine and ethnic medicine of the autonomous region launched the fourth national survey of traditional Chinese medicine resources with a special fund of 12 million yuan from the central government It is reported that in 2012, Xinjiang allocated a total of 67.76 million yuan of funds for the development of ethnic medicine for the basic research of ethnic medicine It can be said that today's support for Xinjiang ethnic medicine is unprecedented Time and place are already available What remains is how to play the initiative and catch up How to span the distance between 300 million yuan and 15 billion yuan although the market share of zucamu granules is expanding day by day, Li Li, Wang Fanyuan's cousin in Beijing, has not heard of the medicine Cold, her habitual choice is Shuanghuanglian price oral liquid In fact, the national medicine industry in Xinjiang, represented by Uygur Medicine, has developed unprecedentedly in recent years, but it is still trapped in the reality of "the smell of wine is afraid of the depth of the alley" Compared with Tibetan, Mongolian, Miao and other ethnic medicine industries, there is still a large gap Last year, the sales revenue of Guizhou's national pharmaceutical industry exceeded 15 billion yuan, Xinjiang just exceeded 300 million yuan, and the varieties with single product output value of more than 50 million yuan are even fewer There is still a long way to go for the development of Xinjiang national medicine industry "The lag of the research on the quality standard of ethnic medicinal materials is the primary problem restricting the development of ethnic medicine industry in our region." Wang Pingshan said In the case of traditional Chinese medicine, there are more than 250 kinds of traditional Chinese medicine with legal quality standards, and about half of them have no quality standards There are about 70 kinds of common medicinal materials in North Africa, southern Europe, Western Asia, Central Asia and other places of origin As for the specific places of origin, they are all hearsay Without accurate information, it is difficult to carry out the key work of standard formulation of medicinal materials, such as the identification of the original medicinal materials and the collection of plant specimens There is no quality standard, which means that many characteristic medicinal materials can not be directly developed and utilized, nor can they be widely used in the field of circulation, which causes great difficulties to the research, production, operation, use, supervision and inspection of drugs The imperfect review and approval system is another problem in the development of ethnic medicine in our region Due to its unique theoretical system, Uighur medicine is quite different from traditional Chinese medicine in the use and processing of medicinal materials, inheritance and translation of ancient books and documents, diagnosis and treatment terms and syndrome diagnosis standards The current measures for the administration of drug registration and the supplementary provisions for the administration of registration of traditional Chinese medicine are not targeted in the evaluation of new Uighur medicine For example, Article 7 of the supplementary provisions stipulates that traditional Chinese medicine compound preparations derived from ancient classical prescriptions can only provide non clinical safety research data and directly apply for production, but the prescriptions must not contain toxic medicinal materials, and the price of toxic medicinal materials, Strychnos, is widely used in Uygur medicine prescriptions through special processing technology; the traditional Chinese medicine compound preparations collected from ancient classical prescriptions are In the early days, there was a lack of collation and protection of ancient books and documents, most of which have been lost, so it is difficult to verify the age of documents Due to the lack of pertinence and operability, so far, there is no application and approval of new medicines for Chinese traditional medicine "The infringement of intellectual property rights should not be underestimated," Zhao said This fear is not groundless 87 Uygur medicines in Xinjiang failed to take effective intellectual property protection 15 Uygur Medicine classics were imitated by more than 90 pharmaceutical manufacturers outside Xinjiang, such as baitiaxiata hot tablets, which were imitated by nearly 30 enterprises The degree of repeated imitations and homogenization was serious Among the existing Uygur Medicine varieties, less than 20% have applied for intellectual property protection, while 2 / 3 of 154 ethnic medicine varieties in Guizhou Province have applied for patent protection; most of the dozens of Tibetan medicine varieties have applied for traditional Chinese medicine variety protection It is also a big problem that the strength of enterprises is weak and the research and development of drugs lags behind Zhao Xinjian said that at present, the production of ethnic pharmaceutical enterprises in our district is generally small in scale and lack of funds The investment of enterprises in R & D is limited Most of the R & D investment is less than 2% of the sales revenue on average Most of the limited funds are invested in "short and smooth" generic drugs Most of the enterprises lack original achievements and the repetitive production of the imitated products is serious In addition, at present, only 9 varieties of Uighur medicine have entered the national medical insurance catalogue, while in some regions, there are some restrictions on national medicine in the centralized bidding procurement Medical insurance threshold